Special Issue "p53 Pathway in Cancer Progression and Cancer Therapy"

A special issue of Biomolecules (ISSN 2218-273X).

Deadline for manuscript submissions: 10 December 2017

Special Issue Editor

Guest Editor
Dr. Libor Macurek

Institute of Molecular Genetics, Prague, Czech Republic
Website | E-Mail
Interests: cell cycle checkpoint; DNA damage response; cancer

Special Issue Information

Dear Colleagues,

Mutation or functional inactivation of the tumor suppressor p53 promotes cancer development; therefore, p53 has been at the center of researchers’ interest for nearly four decades. Various stress response pathways converge on p53, which, by triggering transcription of target genes, controls essential cell fate decisions, ranging from a temporal cell cycle arrest to permanent senescence or apoptosis. In addition to these canonical roles, p53 is implicated in a plethora of other functions, including DNA repair, miRNA production, autophagy, energy metabolism, and stem cell differentiation. There is now emerging evidence that deficient p53 response, not only contributes to tumorigenesis, but could be also exploited in targeted cancer therapy. It has been shown that loss of p53 in cancer cells shows synthetic lethality with certain forms of chemotherapy. Discovery that p53 reactivation leads to tumor regression in animal models boosted the development of several small molecule antagonists of MDM2, which allow p53 stabilization and the induction of cell death in p53 proficient tumors. Finally, gain-of-function mutations of p53 promote stemness of cancer stem cells and, therefore, specific targeting of the mutant p53 could prevent tumor progression.

We encourage scientists to submit their original work or review articles focused on the novel roles of p53 in cell physiology and cancer development, or on the exploitation of p53 pathway in cancer therapy. Both translational and basic research papers are welcome.

Dr. Libor Macurek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 650 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • p53
  • cancer
  • tumor suppressor
  • DNA damage response
  • Cell cycle checkpoint
  • small-molecule inhibitor
  • cell death
  • synthetic lethality

Published Papers

This special issue is now open for submission.

Journal Contact

MDPI AG
Biomolecules Editorial Office
St. Alban-Anlage 66, 4052 Basel, Switzerland
E-Mail: 
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18
Editorial Board
Contact Details Submit to Special Issue Edit a special issue Review for Biomolecules
logo
loading...
Back to Top